The biopharma industry stands at a transformative juncture as it reflects on the achievements of the past year and anticipates the evolving client requirements that will shape 2025 and beyond. Key insights from Subodh Deshmukh, CEO of Aragen Bioscience, highlight the crucial areas of focus for
Thermo Fisher Scientific is taking bold steps toward revolutionizing drug development through its innovative Accelerator Drug Development program. This strategy aims to streamline the complex process from preclinical stages to commercialization by integrating its contract research organization
Antibody development is integral to pushing the boundaries of research, diagnostics, and therapeutics. Characterized by their high specificity and affinity, antibodies are critical for detecting and neutralizing biological targets, leading to significant breakthroughs across various scientific
California, often recognized as a trendsetter in healthcare policy, continues to forge its path with several new laws aimed at improving various aspects of the healthcare system. As the country anticipates shifts in federal healthcare policy under President-elect Donald Trump, California's
Amid growing discontent with the Turkish healthcare system, a coalition of health workers has taken decisive action to protest against new regulations they argue prioritize profit over patient care. Beginning with a five-day work stoppage on January 6, these protests culminated in a general
The pharmaceutical and biotechnology sectors are witnessing a whirlwind of significant developments, from legal disputes over acquisition terms to pivotal personnel changes and strategic restructuring initiatives. These shifts are emblematic of an industry in constant evolution, driven by
